Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Elsevier uses machine learning to benefit pharmacovigilance

Posted on November 7th, 2019 by

Pharmacovigilance

Monitoring the scientific literature for adverse drug reactions (ADRs) is critical to maintaining drug safety, and there is no room for error. As regulations tighten, pharmacovigilance teams are seeking better strategies and methods for ensuring that all ADRs are identified in the most effective and efficient way possible.

(more…)

New Study Offers Insight into Alzheimer’s Disease Research Landscape

Posted on September 9th, 2019 by

Pharma R&D

The sixth leading cause of death in the U.S., and estimated to affect approximately 45 million people worldwide, Alzheimer’s is a progressive brain disease that causes memory loss and overall mental deterioration. Coinciding with World Alzheimer’s Month, Elsevier just released a report (which you can download here) analyzing Alzheimer’s research spanning the last 50 years in order to present a comprehensive overview of the research landscape for this irreversible condition.

(more…)

Elsevier research will be featured at upcoming Safety Pharmacology Society meeting

Posted on September 4th, 2019 by

Pharma R&D

Network showing human adverse events that are concordant in one or more species (Source: Matthew Clark & Thomas Steiger-Hartmann, Regulatory Toxicology and Pharmacology, July 2018)

The 2019 Safety Pharmacology Society meeting will be in Barcelona from September 23-26, and the event is bringing together industry professionals to share best practices, enjoy networking opportunities, hear keynote speeches from thought leaders, and learn about hot research topics from experts in the field.

(more…)

Cannibidiol is All the Rage – Is Pharma Getting in on the CBD Craze?

Posted on August 14th, 2019 by

Pharma R&D

Few substances on earth have been surrounded by more confusion than marijuana. Harmless plant or illicit drug? Medicinal or recreational? Legal or illegal (or partially legal)? And what should we make of all these things associated with marijuana, like hemp and CBD oil?

(more…)

The Beneficial Impacts of Real-World Evidence in Drug Development

Posted on August 1st, 2019 by

Pharma R&D

Advances in technology, increased investment in digital solutions and the creation of more powerful analytics are all contributing to a growing interest in utilizing real-world evidence (RWE) in drug discovery & development. Following up on my previous post that goes into detail on what RWE is and why the industry is increasingly drawn to it, I now want to discuss its role and impact in the drug development life cycle.

(more…)

Why is the Pharma Industry Buzzing About Real-World Evidence?

Posted on July 30th, 2019 by

Pharma R&D

You have almost certainly heard the terms Real-World Data (RWD) and Real-World Evidence (RWE) – but are you still unsure about exactly what these things are and why they’re important? Let’s break it down.

(more…)

  1. 1
  2. 2
  3. 3
  4. 67


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.